{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:23:15Z","timestamp":1782814995554,"version":"3.54.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["I01HX002422"],"award-info":[{"award-number":["I01HX002422"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["SDR 02-237"],"award-info":[{"award-number":["SDR 02-237"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["98-004"],"award-info":[{"award-number":["98-004"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.amjmed.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T19:02:46Z","timestamp":1731697366000},"page":"639-649.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Lower Risk of Death and Kidney Failure Associated with Higher Target (vs Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF"],"prefix":"10.1016","volume":"138","author":[{"given":"Mo-Kyung","family":"Sin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Allman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Faselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia J.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zeng-Treitler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkatesh K.","family":"Raman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Sheriff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charity J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6832-6424","authenticated-orcid":false,"given":"Ali","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.amjmed.2024.10.019_bib0001","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.jacc.2021.12.011","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"36","key":"10.1016\/j.amjmed.2024.10.019_bib0002","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.019_bib0003","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure","volume":"325","author":"Yusuf","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.019_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ejhf.937","article-title":"Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD treatment trial","volume":"20","author":"Lam","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.amjmed.2024.10.019_bib0005","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.amjmed.2019.06.053","article-title":"Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial","volume":"133","author":"Lam","year":"2020","journal-title":"Am J Med"},{"issue":"23","key":"10.1016\/j.amjmed.2024.10.019_bib0006","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"issue":"9704","key":"10.1016\/j.amjmed.2024.10.019_bib0007","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.019_bib0008","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003956","article-title":"Dose of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and outcomes in heart failure: a meta-analysis","volume":"10","author":"Khan","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.019_bib0009","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2215\/CJN.08801010","article-title":"Chronic kidney disease in octogenarians","volume":"6","author":"Shastri","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.019_bib0010","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1002\/ehf2.14787","article-title":"Artificial intelligence approaches for phenotyping heart failure in U.S. Veterans Health Administration electronic health record","volume":"11","author":"Shao","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.019_bib0011","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/ejhf.3210","article-title":"Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. veterans with heart failure","volume":"26","author":"Patel","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.019_bib0012","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"40","key":"10.1016\/j.amjmed.2024.10.019_bib0013","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1093\/eurheartj\/ehz395","article-title":"Digoxin-mortality: randomized vs. observational comparison in the DIG trial","volume":"40","author":"Aguirre Davila","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2024.10.019_bib0014","article-title":"The prevalent-user bias in observational studies and the importance of new-user design (letter to the editor)","author":"Ahmed","year":"2020","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.019_bib0015","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.amjmed.2011.10.013","article-title":"Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease","volume":"125","author":"Ahmed","year":"2012","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.019_bib0016","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.amjmed.2023.03.017","article-title":"Renin-angiotensin inhibition and outcomes in HFrEF and advanced kidney disease","volume":"136","author":"Patel","year":"2023","journal-title":"Am J Med"},{"issue":"25","key":"10.1016\/j.amjmed.2024.10.019_bib0017","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.019_bib0018","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.amjmed.2024.10.019_bib0019","unstructured":"Arnold N. VHA Death Ascertainment File (DAF) and other data sources for mortality ascertainment. 2024. Available at: https:\/\/www.hsrd.research.va.gov\/for_researchers\/cyber_seminars\/archives\/6303-notes.pdf Accessed October 18, 2024."},{"issue":"1","key":"10.1016\/j.amjmed.2024.10.019_bib0020","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1681\/ASN.2018050521","article-title":"Survival among veterans obtaining dialysis in VA and non-VA settings","volume":"30","author":"Wang","year":"2019","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.019_bib0021","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.amjmed.2024.10.019_bib0022","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.amjmed.2024.10.019_bib0023","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s00198-019-05048-w","article-title":"Assessing risk factors of non-fatal outcomes amid a competing risk of mortality: the example of hip fracture","volume":"30","author":"Buzkova","year":"2019","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.1016\/j.amjmed.2024.10.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0255313","article-title":"Competing risk of mortality in association studies of non-fatal events","volume":"16","author":"Buzkova","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.amjmed.2024.10.019_bib0025","series-title":"Observational Studies","first-page":"105","article-title":"Sensitivity to hidden bias","author":"Rosenbaum","year":"2002"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.019_bib0026","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.019_bib0027","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.amjmed.2018.07.008","article-title":"Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate","volume":"131","author":"Lam","year":"2018","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.019_bib0028","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2019.05.064","article-title":"Digoxin discontinuation and outcomes in patients with heart failure with reduced ejection fraction","volume":"74","author":"Malik","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.019_bib0029","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.amjmed.2024.10.019_bib0030","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.cardfail.2006.05.008","article-title":"Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis","volume":"12","author":"Ahmed","year":"2006","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.019_bib0031","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/01.CIR.0000138934.28340.ED","article-title":"National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction","volume":"110","author":"Masoudi","year":"2004","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.amjmed.2024.10.019_bib0032","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1093\/eurheartj\/ehy621","article-title":"Association between renin-angiotensin system inhibitor use and mortality\/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study","volume":"39","author":"Savarese","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2024.10.019_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170733","article-title":"The renin-angiotensin system and cardiovascular autonomic control in aging","volume":"150","author":"Miller","year":"2022","journal-title":"Peptides"},{"issue":"3","key":"10.1016\/j.amjmed.2024.10.019_bib0034","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/cells10030650","article-title":"The tissue renin-angiotensin system and its role in the pathogenesis of major human diseases: Quo Vadis?","volume":"10","author":"Saravi","year":"2021","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.019_bib0035","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.019_bib0036","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.amjmed.2024.10.019_bib0037","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2024.10.019_bib0038","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1681\/ASN.2006121372","article-title":"Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency","volume":"18","author":"Hou","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.amjmed.2024.10.019_bib0039","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"issue":"9169","key":"10.1016\/j.amjmed.2024.10.019_bib0040","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.amjmed.2024.10.019_bib41","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1177\/0962280215584401","article-title":"The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes","volume":"26","author":"Austin","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"28","key":"10.1016\/j.amjmed.2024.10.019_bib42","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934324007101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T06:22:11Z","timestamp":1778653331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934324007101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0002934324007101"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.019","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lower Risk of Death and Kidney Failure Associated with Higher Target (vs Below-Target) Doses of RAS Inhibitors in Octogenarians with HFrEF","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}